Goldman Sachs Group Inc. Has $153,000 Holdings in XBiotech Inc. $XBIT

Goldman Sachs Group Inc. lessened its stake in shares of XBiotech Inc. (NASDAQ:XBIT) by 12.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 47,182 shares of the biopharmaceutical company’s stock after selling 6,548 shares during the period. Goldman Sachs Group Inc. owned about 0.15% of XBiotech worth $153,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Hsbc Holdings PLC acquired a new stake in XBiotech during the 1st quarter worth about $52,000. Deutsche Bank AG acquired a new stake in XBiotech during the 4th quarter worth about $120,000. Charles Schwab Investment Management Inc. raised its holdings in XBiotech by 15.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 67,355 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 8,918 shares during the period. Nuveen LLC acquired a new stake in XBiotech during the 1st quarter worth about $81,000. Finally, Bank of America Corp DE raised its holdings in XBiotech by 42.0% during the 4th quarter. Bank of America Corp DE now owns 19,888 shares of the biopharmaceutical company’s stock worth $79,000 after buying an additional 5,887 shares during the period. Institutional investors and hedge funds own 55.70% of the company’s stock.

XBiotech Price Performance

Shares of XBIT opened at $2.69 on Tuesday. The company has a market capitalization of $82.02 million, a price-to-earnings ratio of -2.92 and a beta of 0.85. XBiotech Inc. has a fifty-two week low of $2.50 and a fifty-two week high of $8.32. The business’s 50-day moving average is $2.96 and its 200-day moving average is $2.97.

XBiotech (NASDAQ:XBIT) last issued its earnings results on Wednesday, August 13th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter.

About XBiotech

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.